Pearce IP BioBlast: w/e 03 Apr 2020

Significant biosimilar activities this week include:

  • On 30 Mar 2020, Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab) and Herticad® (trastuzumab), with a launch expected in 2020.


  • On 30 March 2020, in response to CoVid-19, Genentech announced it would extend physician payment terms for Lucentis® (ranibizumab) purchases to 120 days, up from the previous 60 day term. These new terms will be implemented from 01 April, 2020, as well as retroactively for Lucentis® purchased on or after March 1, 2020.


  • On 01 April 2020, a new study reported that Truxima® (rituximab) is comparable to the originator in terms of efficacy and safety in the treatment of multiple sclerosis. Rituximab is not currently indicated for multiple sclerosis but it is used off-label in some cases and is under investigation as a potential treatment.


  • On 02 April 2020, Pfizer announced EC approval of Ruxience® (Rituximab) for the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

November 9, 2020

Please reload

Search by tags